CCDC50

Across TCGA pan-cancer cohorts, CCDC50 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC50 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CCDC50 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC50 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, OV, and LIHC are the cancer types where CCDC50 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.198	0.829	.001	20	view →
OV	DFS	Median	All	0.092	0.541	<.001	18	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.928	0.306	.019	10	view →
HNSC	DFS	Median	II,III,IV	0.411	0.686	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCDC50–READ (OS)

Open the READ breakdown →